It has been a rollercoaster week for global stock markets, which first dived amid US tariffs, trade war and recession concerns only to whipsaw back when President Trump placed a 90-day hold on levies.

It’s so far left the FTSE 100 around 2 per cent in the red. Small-caps, by contrast, fared much better, ending the week broadly unchanged. That said, the ride to get this point was a fairly scary one, full of undulations.

This comparative outperformance of the blue-chip index shouldn’t fool anyone. The growth company benchmark is in serious decline amid lack of interest in the sector, low liquidity and a defection of talent to the private market.

In the year to date, the AIM All-Share is down 11 per cent at 645, but standing back, the picture is grim. It has more than halved in value from its peak in early September 2021.

An early victim of the trade war was Belluscura, which fell 40 per cent.

It makes portable oxygen concentrators for people who struggle to breathe and withdrew its financial guidance for the current year due to the new US tariffs on China.

The medical device maker said a ‘significant proportion’ of its oxygen concentrators, raw materials and component parts are currently manufactured in China, where President Trump has imposed levies of up to 125 per cent on some goods.

The week’s biggest loser was mini-microcap Nativo Resources, which dropped 46 per cent and is currently valued at £322,000. The catalysts appear to have been the issue of shares and warrants to acquire the Morrocota Gold Mine in Peru.

It has been a rollercoaster week for global stock markets 

A share issue on an altogether bigger scale was behind the 20 per cent drop in Gemfields. The emerald miner and marketer raised around £23 million via a rights issue. 

The funding will be used to put the company on firmer financial footing following a challenging phase of trading. It will also provide the headroom to complete a second processing plant.

It was a rough week for investors in podcast platform Audioboom (down 23 per cent), which delivered what Cavendish described as a ‘robust’ set of prelims accompanied by an upbeat trading update. The broker values the stock at 1,300p, more than three times the current price. Chairman Michael Tobin clearly sees some value as he dipped into the market to buy shares.

Research from Peel Hunt last week warned that UK small-caps are being picked off by cashed-up predators, with bargain-basement valuations and a lack of investor appetite cited for the trend.

As if to underline the point, Induction Healthcare, which connects patients and doctors digitally, has agreed to be bought out by Canadian software group VitalHub for £9.7 million. The shares ended the week 58 per cent higher.

Shares in Atome jumped 55 per cent after the company signed a £355 million construction contract for its flagship green fertiliser plant in Paraguay. Swiss engineering group Casale will deliver the project, which aims to produce 260,000 tonnes of low-carbon fertiliser annually using 100 per cent renewable power. At 43p, the shares are a snip, says Stifel. The American bank thinks they are worth 130p.

It was a case of back from the dead for Minoan, whose shares advanced 48 per cent after a collapse prompted by worries over its financial position. Behind the scenes, the holiday group is scrambling to finalise a rescue deal with DAGG LLP, its main lender, which is owed around £1.2 million and has been charging default interest of 22 per cent since January. 

The rise may foretell something more positive. Still, the stock has lost around 62 per cent of its value this year, and trading will be suspended on May 1 if no resolution is found.

Cobra Resources rose 23 per cent after telling investors it will soon start sonic drilling at its Boland rare earth project in South Australia. The programme, which uses high-frequency resonant energy, will comprise up to 15 holes to assess mineralisation and inform a future resource estimate. It follows a prior air core drill programme that proved successful.

Directa Plus advanced 7 per cent after telling investors it has generated €2 million of revenue in its first quarter, a 40 per cent improvement on last year.

Renalytix shares moved 3 per cent higher on an upbeat trading update, revealing a 20 per cent rise in third-quarter revenue. The company, which specialises in AI-enabled in vitro diagnostics, processed more than 1,000 billable kidney tests in the quarter.

Finally, returning to the watch list. We flagged 4Global, the sports analytics specialist valued at just over one times forecast revenues. This week it landed a chunky £500,000 contract with UK Sport that paves the way for similar deals.

For all the breaking small- and mid-cap news go to www.proactiveinevstors.co.uk

DIY INVESTING PLATFORMS

AJ Bell

AJ Bell

Easy investing and ready-made portfolios

Hargreaves Lansdown

Hargreaves Lansdown

Free fund dealing and investment ideas

interactive investor

interactive investor

Flat-fee investing from £4.99 per month

Saxo

Saxo

Get £200 back in trading fees

Trading 212

Trading 212

Free dealing and no account fee

Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.

Compare the best investing account for you